Skip to content

Study · Randomized controlled trial · n = 8 · 2010

3 results

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.

Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, Heptulla RA

Diabetes care23 Mar 2010Cited by 64 (Europe PMC)

PMID20332358 (opens in a new tab)PMCIDPMC2875441 (opens in a new tab)DOI10.2337/dc09-1959 (opens in a new tab)PepBankPUB-20332358
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adolescents with type 1 diabetes, premeal exenatide at 1.25 and 2.5 microg, with prandial insulin reduced by 20%, reduced 300-minute glucose excursions versus insulin monotherapy.

    In plain wordsIn adolescents with type 1 diabetes, mealtime exenatide with less insulin lowered glucose rises compared with insulin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucose excursions over 300 min
    Study

    n = 8

    Comparator
    insulin monotherapy
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.25 and 2.5 microg premealAs given in this study (human).

    Source sentences

    Summary
    Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001).
    3 context sentences
    Summary · context
    Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide.
    Summary · context
    Two doses of exenatide (1.25 and 2.5 microg) were compared with insulin monotherapy.
    Summary · context
    Prandial insulin dose was reduced by 20%.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adolescents with type 1 diabetes, premeal exenatide did not suppress glucagon.

    In plain wordsIn adolescents with type 1 diabetes, mealtime exenatide did not lower glucagon.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucagon suppression
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.25 and 2.5 microg premealAs given in this study (human).

    Source sentences

    Summary
    Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004).
    3 context sentences
    Summary · context
    Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide.
    Summary · context
    Two doses of exenatide (1.25 and 2.5 microg) were compared with insulin monotherapy.
    Summary · context
    Prandial insulin dose was reduced by 20%.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adolescents with type 1 diabetes, premeal exenatide delayed gastric emptying.

    In plain wordsIn adolescents with type 1 diabetes, mealtime exenatide slowed stomach emptying.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGastric emptying
    Study

    n = 8

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.25 and 2.5 microg premealAs given in this study (human).

    Source sentences

    Summary
    Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004).
    3 context sentences
    Summary · context
    Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide.
    Summary · context
    Two doses of exenatide (1.25 and 2.5 microg) were compared with insulin monotherapy.
    Summary · context
    Prandial insulin dose was reduced by 20%.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00456300

Role of Exenatide in Type 1 Diabetes

Montefiore Medical Centern = 11Mar 2007 to Mar 2009

Type 1 Diabetes

Trial pageClinicalTrials.govUpdated 26 Feb 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.